CVS
stock NYSEKey stats
- Open
- $93.16
- -0.13%
- Close
- $93.32
- +0.04%
- Current
- $93.32
- Prev close
- $93.28
- Today
- 6.48M
- 3-mo avg
- 8.18M
Fundamentals
Each ratio reads FY2025 figures against the latest price, graded so the quality shows at a glance.
At 67x, the price is steep relative to profit; the stock leans heavily on growth that has yet to arrive.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 2.9% yield is a healthy, generally sustainable level of cash income.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 0.4% margin is thin; little of each revenue dollar survives as profit.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 2.4% return on equity is weak; owners' capital is barely being put to work.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 0.7% return on assets is low; the asset base is generating little profit.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 2.37, the company leans heavily on borrowing, which adds risk if results weaken.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 0.84, short-term assets fall short of short-term bills; liquidity is tight.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 7.8% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income fell 61.7% from the prior year; profit is shrinking.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financials
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Net income | $8.0B | $4.3B | $8.3B | $4.6B | $1.8B |
| Diluted EPS | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
| Dividend / share | $2.00 | $2.20 | $2.42 | $2.66 | $2.66 |
| Total assets | $233.0B | $228.3B | $249.7B | $253.2B | $253.5B |
| Total liabilities | $157.6B | $156.5B | $173.1B | $177.5B | $178.2B |
| Shareholder equity | $74.8B | $71.8B | $76.6B | $75.6B | $75.2B |
| Q3-2023 | Q1-2024 | Q2-2024 | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $89.8B | $88.4B | $91.2B | $95.4B | $94.6B | $98.9B | $102.9B | $100.4B |
| Net income | $2.3B | $1.1B | $1.8B | $87.0M | $1.8B | $1.0B | -$4.0B | $2.9B |
| Diluted EPS | $1.75 | $0.88 | $1.41 | $0.07 | $1.41 | $0.80 | $-3.13 | $2.30 |
| Dividend / share | $0.60 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 | $0.67 |
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report